TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06401395: Clinical Evaluation of A neW Management Strategy for Patients With pArKinson's disEase usiNg an Innovative telemonitorING Device : AWAKENING Study

Sponsor: DIAMPARK · Phase: PHASE2 · Area: CNS_NEUROLOGY · Target Enrollment: 300 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$12,416,000

Rescue Site Savings

+$8,186,800

Unlock Full NCT06401395 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06401395 Rescue Dossier →